Global Bi-Specific MAbS Market Research Report 2024

Publication ID:

PB505245778

Publication Date:

May 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.
The global Bi-Specific MAbS market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Bi-Specific MAbS is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bi-Specific MAbS is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Bi-Specific MAbS in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Bi-Specific MAbS include Johnson and Johnson, Novartis AG, Hoffmann-La Roche Ltd., Chugai Pharmaceutical, Bayer AG, Thermo Fisher Scientific, Bistro-Myers Squibb, Mylan N.V. and Daiichi Sankyo Company, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Bi-Specific MAbS, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific MAbS.
Report Scope
The Bi-Specific MAbS market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Bi-Specific MAbS market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bi-Specific MAbS companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Johnson and Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Chugai Pharmaceutical
Bayer AG
Thermo Fisher Scientific
Bistro-Myers Squibb
Mylan N.V.
Daiichi Sankyo Company
Abbott
AstraZeneca
Eli Lilly
Merck and Co.
Amgen
Pfizer
GlaxoSmithKline plc
Roche
Segment by Type
Catumaxomab
Blinatumomab
Duligotumab
SAR 156597
Segment by Application
Cancer
Autoimmune Diseases
Inflammatory Diseases
Infectious Diseases
Microbial Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bi-Specific MAbS companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bi-Specific MAbS Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Catumaxomab
1.2.3 Blinatumomab
1.2.4 Duligotumab
1.2.5 SAR 156597
1.3 Market by Application
1.3.1 Global Bi-Specific MAbS Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Autoimmune Diseases
1.3.4 Inflammatory Diseases
1.3.5 Infectious Diseases
1.3.6 Microbial Diseases
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bi-Specific MAbS Market Perspective (2019-2030)
2.2 Bi-Specific MAbS Growth Trends by Region
2.2.1 Global Bi-Specific MAbS Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bi-Specific MAbS Historic Market Size by Region (2019-2024)
2.2.3 Bi-Specific MAbS Forecasted Market Size by Region (2025-2030)
2.3 Bi-Specific MAbS Market Dynamics
2.3.1 Bi-Specific MAbS Industry Trends
2.3.2 Bi-Specific MAbS Market Drivers
2.3.3 Bi-Specific MAbS Market Challenges
2.3.4 Bi-Specific MAbS Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bi-Specific MAbS Players by Revenue
3.1.1 Global Top Bi-Specific MAbS Players by Revenue (2019-2024)
3.1.2 Global Bi-Specific MAbS Revenue Market Share by Players (2019-2024)
3.2 Global Bi-Specific MAbS Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bi-Specific MAbS Revenue
3.4 Global Bi-Specific MAbS Market Concentration Ratio
3.4.1 Global Bi-Specific MAbS Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bi-Specific MAbS Revenue in 2023
3.5 Bi-Specific MAbS Key Players Head office and Area Served
3.6 Key Players Bi-Specific MAbS Product Solution and Service
3.7 Date of Enter into Bi-Specific MAbS Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bi-Specific MAbS Breakdown Data by Type
4.1 Global Bi-Specific MAbS Historic Market Size by Type (2019-2024)
4.2 Global Bi-Specific MAbS Forecasted Market Size by Type (2025-2030)
5 Bi-Specific MAbS Breakdown Data by Application
5.1 Global Bi-Specific MAbS Historic Market Size by Application (2019-2024)
5.2 Global Bi-Specific MAbS Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bi-Specific MAbS Market Size (2019-2030)
6.2 North America Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Bi-Specific MAbS Market Size by Country (2019-2024)
6.4 North America Bi-Specific MAbS Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Bi-Specific MAbS Market Size (2019-2030)
7.2 Europe Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Bi-Specific MAbS Market Size by Country (2019-2024)
7.4 Europe Bi-Specific MAbS Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific MAbS Market Size (2019-2030)
8.2 Asia-Pacific Bi-Specific MAbS Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Bi-Specific MAbS Market Size by Region (2019-2024)
8.4 Asia-Pacific Bi-Specific MAbS Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Bi-Specific MAbS Market Size (2019-2030)
9.2 Latin America Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Bi-Specific MAbS Market Size by Country (2019-2024)
9.4 Latin America Bi-Specific MAbS Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific MAbS Market Size (2019-2030)
10.2 Middle East & Africa Bi-Specific MAbS Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Bi-Specific MAbS Market Size by Country (2019-2024)
10.4 Middle East & Africa Bi-Specific MAbS Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Johnson and Johnson
11.1.1 Johnson and Johnson Company Detail
11.1.2 Johnson and Johnson Business Overview
11.1.3 Johnson and Johnson Bi-Specific MAbS Introduction
11.1.4 Johnson and Johnson Revenue in Bi-Specific MAbS Business (2019-2024)
11.1.5 Johnson and Johnson Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Bi-Specific MAbS Introduction
11.2.4 Novartis AG Revenue in Bi-Specific MAbS Business (2019-2024)
11.2.5 Novartis AG Recent Development
11.3 Hoffmann-La Roche Ltd.
11.3.1 Hoffmann-La Roche Ltd. Company Detail
11.3.2 Hoffmann-La Roche Ltd. Business Overview
11.3.3 Hoffmann-La Roche Ltd. Bi-Specific MAbS Introduction
11.3.4 Hoffmann-La Roche Ltd. Revenue in Bi-Specific MAbS Business (2019-2024)
11.3.5 Hoffmann-La Roche Ltd. Recent Development
11.4 Chugai Pharmaceutical
11.4.1 Chugai Pharmaceutical Company Detail
11.4.2 Chugai Pharmaceutical Business Overview
11.4.3 Chugai Pharmaceutical Bi-Specific MAbS Introduction
11.4.4 Chugai Pharmaceutical Revenue in Bi-Specific MAbS Business (2019-2024)
11.4.5 Chugai Pharmaceutical Recent Development
11.5 Bayer AG
11.5.1 Bayer AG Company Detail
11.5.2 Bayer AG Business Overview
11.5.3 Bayer AG Bi-Specific MAbS Introduction
11.5.4 Bayer AG Revenue in Bi-Specific MAbS Business (2019-2024)
11.5.5 Bayer AG Recent Development
11.6 Thermo Fisher Scientific
11.6.1 Thermo Fisher Scientific Company Detail
11.6.2 Thermo Fisher Scientific Business Overview
11.6.3 Thermo Fisher Scientific Bi-Specific MAbS Introduction
11.6.4 Thermo Fisher Scientific Revenue in Bi-Specific MAbS Business (2019-2024)
11.6.5 Thermo Fisher Scientific Recent Development
11.7 Bistro-Myers Squibb
11.7.1 Bistro-Myers Squibb Company Detail
11.7.2 Bistro-Myers Squibb Business Overview
11.7.3 Bistro-Myers Squibb Bi-Specific MAbS Introduction
11.7.4 Bistro-Myers Squibb Revenue in Bi-Specific MAbS Business (2019-2024)
11.7.5 Bistro-Myers Squibb Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Detail
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Bi-Specific MAbS Introduction
11.8.4 Mylan N.V. Revenue in Bi-Specific MAbS Business (2019-2024)
11.8.5 Mylan N.V. Recent Development
11.9 Daiichi Sankyo Company
11.9.1 Daiichi Sankyo Company Company Detail
11.9.2 Daiichi Sankyo Company Business Overview
11.9.3 Daiichi Sankyo Company Bi-Specific MAbS Introduction
11.9.4 Daiichi Sankyo Company Revenue in Bi-Specific MAbS Business (2019-2024)
11.9.5 Daiichi Sankyo Company Recent Development
11.10 Abbott
11.10.1 Abbott Company Detail
11.10.2 Abbott Business Overview
11.10.3 Abbott Bi-Specific MAbS Introduction
11.10.4 Abbott Revenue in Bi-Specific MAbS Business (2019-2024)
11.10.5 Abbott Recent Development
11.11 AstraZeneca
11.11.1 AstraZeneca Company Detail
11.11.2 AstraZeneca Business Overview
11.11.3 AstraZeneca Bi-Specific MAbS Introduction
11.11.4 AstraZeneca Revenue in Bi-Specific MAbS Business (2019-2024)
11.11.5 AstraZeneca Recent Development
11.12 Eli Lilly
11.12.1 Eli Lilly Company Detail
11.12.2 Eli Lilly Business Overview
11.12.3 Eli Lilly Bi-Specific MAbS Introduction
11.12.4 Eli Lilly Revenue in Bi-Specific MAbS Business (2019-2024)
11.12.5 Eli Lilly Recent Development
11.13 Merck and Co.
11.13.1 Merck and Co. Company Detail
11.13.2 Merck and Co. Business Overview
11.13.3 Merck and Co. Bi-Specific MAbS Introduction
11.13.4 Merck and Co. Revenue in Bi-Specific MAbS Business (2019-2024)
11.13.5 Merck and Co. Recent Development
11.14 Amgen
11.14.1 Amgen Company Detail
11.14.2 Amgen Business Overview
11.14.3 Amgen Bi-Specific MAbS Introduction
11.14.4 Amgen Revenue in Bi-Specific MAbS Business (2019-2024)
11.14.5 Amgen Recent Development
11.15 Pfizer
11.15.1 Pfizer Company Detail
11.15.2 Pfizer Business Overview
11.15.3 Pfizer Bi-Specific MAbS Introduction
11.15.4 Pfizer Revenue in Bi-Specific MAbS Business (2019-2024)
11.15.5 Pfizer Recent Development
11.16 GlaxoSmithKline plc
11.16.1 GlaxoSmithKline plc Company Detail
11.16.2 GlaxoSmithKline plc Business Overview
11.16.3 GlaxoSmithKline plc Bi-Specific MAbS Introduction
11.16.4 GlaxoSmithKline plc Revenue in Bi-Specific MAbS Business (2019-2024)
11.16.5 GlaxoSmithKline plc Recent Development
11.17 Roche
11.17.1 Roche Company Detail
11.17.2 Roche Business Overview
11.17.3 Roche Bi-Specific MAbS Introduction
11.17.4 Roche Revenue in Bi-Specific MAbS Business (2019-2024)
11.17.5 Roche Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Johnson and Johnson
Novartis AG
Hoffmann-La Roche Ltd.
Chugai Pharmaceutical
Bayer AG
Thermo Fisher Scientific
Bistro-Myers Squibb
Mylan N.V.
Daiichi Sankyo Company
Abbott
AstraZeneca
Eli Lilly
Merck and Co.
Amgen
Pfizer
GlaxoSmithKline plc
Roche

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂